Gaucher disease and myeloma

Critical Reviews in Oncogenesis

Volumn 18, Issue 3, 2013, Pages 247-268

  Ayto, Robert ^a   Hughes, Derralynn A ^b  

^a WEST LONDON MENTAL HEALTH NHS TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

GaucherMGUS; Myeloma; Tumor associated macrophages (TAMs)

Indexed keywords

ANTINEOPLASTIC AGENT; BECLIN 1; BORTEZOMIB; CERAMIDE; CHITOTRIOSIDASE; CLODRONIC ACID; CYTOKINE; DICKKOPF 1 PROTEIN; DOXORUBICIN; FREE RADICAL; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; IMMUNOMODULATING AGENT; LENALIDOMIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MELPHALAN; MULTIDRUG RESISTANCE PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PREDNISOLONE; PROTEASOME INHIBITOR; SPHINGOLIPID; THALIDOMIDE; VASCULAR CELL ADHESION MOLECULE 1; ZOLEDRONIC ACID;

ACUTE LEUKEMIA; AMYLOIDOSIS; ANTIGEN PRESENTATION; ARTICLE; AUTOPHAGY; B CELL LYMPHOMA; BONE CANCER; BONE MARROW; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER RISK; CARCINOGENESIS; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOPENIA; DYSGERMINOMA; ENZYME REPLACEMENT; GAMMOPATHY; GAUCHER DISEASE; GENE MUTATION; GENETIC LINKAGE; GLIOBLASTOMA; HEMANGIOENDOTHELIOMA; HUMAN; INCIDENCE; LARGE CELL LYMPHOMA; LEUKEMIA; LIPID METABOLISM; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT TRANSFORMATION; MARGINAL ZONE LYMPHOMA; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOPOROSIS; PANCREAS CANCER; PARAPROTEINEMIA; PATHOPHYSIOLOGY; PERIPHERAL T CELL LYMPHOMA; PLASMACYTOMA; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

AUTOPHAGY; BONE MARROW; CELL TRANSFORMATION, NEOPLASTIC; CELLULAR MICROENVIRONMENT; GAUCHER DISEASE; HUMANS; INCIDENCE; INFLAMMATION; MULTIPLE MYELOMA; PARAPROTEINEMIAS; RISK; SPHINGOLIPIDS;

EID: 84875303631     PISSN: 08939675     EISSN: 21626448     Source Type: Journal    
DOI: 10.1615/CritRevOncog.2013006061     Document Type: Article

References (200)

1. Koprivica V, Stone DL, Park JK, Callahan M, Frisch A, Cohen IJ, Tayebi N, Sidransky E. Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. American Journal of Human Genetics. 2000;66(6):1777-86.
2. Pastores GM. Gaucher's Disease. Pathological features. Bailliere's Clinical Haematology. 1997;10(4):739-49.
3. Shachar T, Lo Bianco C, Recchia A, Wiessner C, Raas-Rothschild A, Futerman AH. Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Movement Disorders: Official Journal of the Movement Disorder Society. 2011;26(9):1593-604.
4. Shiran A, Brenner B, Laor A, Tatarsky I. Increased risk of cancer in patients with Gaucher disease. Cancer. 1993;72(1):219-24.
5. de Fost M, Vom Dahl S, Weverling GJ, Brill N, Brett S, Haussinger D, Hollak CE. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells, Molecules & Diseases. 2006;36(1):53-8.
6. Zimran A, Liphshitz I, Barchana M, Abrahamov A, Elstein D. Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells, Molecules & Diseases. 2005;34(3):197-200.
7. Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood. 2005;105(12):4569-72.
8. Kang JC, Chen JS, Lee CH, Chang JJ, Shieh YS. Intratumoral macrophage counts correlate with tumor progression in colorectal cancer. Journal of Surgical Oncology. 2010;102(3):242-8.
9. Brautbar A, Elstein D, Pines G, Abrahamov A, Zimran A. Effect of enzyme replacement therapy on gammopathies in Gaucher disease. Blood Cells, Molecules & Diseases. 2004;32(1):214-7.
10. de Fost M, Out TA, de Wilde FA, Tjin EP, Pals ST, van Oers MH, Boot RG, Aerts JF, Maas M, Vom Dahl S, Hollak CE. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Annals of Hematology. 2008;87(6):439-49.
11. Biggar RJ, Kirby KA, Atkinson J, McNeel TS, Engels E. Cancer risk in elderly persons with HIV/AIDS. J Acquir Immune Defic Syndr. 2004;36(3):861-8.
12. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356(9244):1795-9.
13. Landgren O, Turesson I, Gridley G, Caporaso NE. Risk of malignant disease among 1525 adult male US Veterans with Gaucher disease. Archives of Internal Medicine. 2007;167(11):1189-94.
14. Lee RE. The pathology of Gaucher disease. Progress in Clinical and Biological Research. 1982;95:177-217.
15. Taddei TH, Kacena KA, Yang M, Yang R, Malhotra A, Boxer M, Aleck KA, Rennert G, Pastores GM, Mistry PK. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. American Journal of Hematology. 2009;84(4):208-14.
16. Lo SM, Stein P, Mullaly S, Bar M, Jain D, Pastores GM, Mistry PK. Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype. American Journal of Hematology. 2010;85(5):340-5.
17. Bertram HC, Eldibany M, Padgett J, Dragon LH. Splenic lymphoma arising in a patient with Gaucher disease. A case report and review of the literature. Archives of Pathology & Laboratory Medicine. 2003;127(5):e242-5.
18. Cho SY, Sastre M. Coexistence of Hodgkin's disease and Gaucher's disease. American Journal of Clinical Pathology. 1976;65(1):103-8.
19. Mark T, Dominguez C, Rywlin AM. Gaucher's disease associated with chronic lymphocytic leukemia. Southern Medical Journal. 1982;75(3):361-3.
20. Brody JD, Advani R, Shin LK, Bingham DB, Rosenberg SA. Splenic diffuse large B-cell lymphoma in a patient with type 1 Gaucher disease: Diagnostic and therapeutic challenges. Annals of Hematology. 2006;85(11):817-20.
21. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ, 3rd. Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades. Cancer. 2004;101(11):2667-74.
22. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ, 3rd. Prevalence of monoclonal gammopathy of undetermined significance. The New England Journal of Medicine. 2006;354(13):1362-9.
23. Wine E, Yaniv I, Cohen IJ. Hyperimmunoglobulinemia in pediatric-onset type 1 Gaucher disease and effects of enzyme replacement therapy. Journal of Pediatric Hematology/Oncology. 2007;29(7):451-7.
24. Pratt PW, Kochwa S, Estren S. Immunoglobulin abnormalities in Gaucher's disease. Report of 16 cases. Blood. 1968;31(5):633-40.
25. Grosbois B, Rose C, Noel E, Serratrice Cde R, Dobbelaere D, Gressin V, Cherin P, Hartmann A, Javier RM, Clerson P, Hachulla E, Jaussaud R. Gaucher disease and monoclonal gammopathy: a report of 17 cases and impact of therapy. Blood Cells, Molecules & Diseases. 2009;43(1):138-9.
26. Saleun JP, Vicariot M, Deroff P, Morin JF. Monoclonal gammopathies in the adult population of Finistere, France. Journal of Clinical Pathology. 1982;35(1):63-8.
27. Hughes D, Cappellini MD, Berger M, Van Droogenbroeck J, de Fost M, Janic D, Marinakis T, Rosenbaum H, Villarubia J, Zhukovskaya E, Hollak C. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. British Journal of Haematology. 2007;138(6):676-86.
28. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings Mayo Clinic. 2003;78(1):21-33.
29. Harder H, Eucker J, Zang C, Possinger K, Muller-Hocker J, Beutler E, Petrides PE. Coincidence of Gaucher's disease due to a 1226G/1448C mutation and of an immunoglobulin G lambda multiple myeloma with Bence-Jones proteinuria. Annals of Hematology. 2000;79(11):640-3.
30. Machaczka M, Lerner R, Klimkowska M, Hagglund H. Treatment of multiple myeloma in patients with Gaucher disease. American Journal of Hematology. 2009;84(10):694-6.
31. Grosbois B, Revest M, Decaux O. [Major hyperferritinemia, autoimmune thrombocytopenic purpura and lymphocytic lymphoma in Gaucher disease]. Presse Med. 2009;38 Suppl 2:2S56-7. Hyperferritinemie majeure, purpura thrombopenique auto-immun et lymphome lymphocytique au cours d'une maladie de Gaucher.
32. Ruestow PC, Levinson DJ, Catchatourian R, Sreekanth S, Cohen H, Rosenfeld S. Coexistence of IgA myeloma and Gaucher's disease. Archives of Internal Medicine. 1980;140(8):1115-6.
33. Brady K, Corash L, Bhargava V. Multiple myeloma arising from monoclonal gammopathy of undetermined significance in a patient with Gaucher's disease. Archives of Pathology & Laboratory Medicine. 1997;121(10):1108-11.
34. Shvidel L, Hurwitz N, Shtalrid M, Zur S, Oliver O, Berrebi A. Complex IgA gammopathy in Gaucher's disease. Leukemia & Lymphoma. 1995;20(1-2):165-8.
35. Cheung WY, Greenberg CR, Bernstein K, Schacter B, Fourie T, Seftel MD. Type I Gaucher disease following chemotherapy for light chain multiple myeloma. Intern Med. 2007;46(15):1255-8.
36. Benjamin D, Joshua H, Djaldetti M, Hazaz B, Pinkhas J. Nonsecretory IgD-kappa multiple myeloma in a patient with Gaucher's disease. Scandinavian Journal of Haematology. 1979;22(2):179-84.
37. Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O'Fallon WM, Kurland LT. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79(7):1817-22.
38. Haran MZ, Feldberg E, Berrebi A. Incidental diagnosis of Gaucher's disease in an elderly patient with lymphoma. Leukemia & Lymphoma. 2001;40(3-4):445-6.
39. Cassiman D, Claes K, Lerut E, Oyen R, Joniau S, Van Damme B, Jaeken J. Bilateral renal cell carcinoma development in long-term Fabry disease. Journal of Inherited Metabolic Disease. 2007;30(5):830-1.
40. Blanco J, Herrero J, Arias LF, Garcia-Miralles N, Gamez C, Barrientos A. Renal variant of Anderson-Fabry disease and bilateral renal cell carcinoma. Pathology, Research and Practice. 2005;200(11-12):857-60.
41. Cybulla M, Kleber M, Walter KN, Kroeber SM, Neumann HP, Engelhardt M. Is Fabry disease associated with leukaemia? British Journal of Haematology. 2006;135(2):264-5.
42. Dikman SH, Goldstein M, Kahn T, Leo MA, Weinreb N. Amyloidosis. An unusual complication of Gaucher's disease. Archives of Pathology & Laboratory Medicine. 1978;102(9):460-2.
43. Elstein D, Rosenmann E, Reinus C, Paz J, Altarescu G, Zimran A. Amyloidosis and gastric bleeding in a patient with Gaucher disease. Journal of Clinical Gastroenterology. 2003;37(3):234-7.
44. Hanash SM, Rucknagel DL, Heidelberger KP, Radin NS. Primary amyloidosis associated with Gaucher's disease. Annals of Internal Medicine. 1978;89(5 Pt 1):639-41.
45. Kaloterakis A, Filiotou A, Koskinas J, Raptis I, Zouboulis C, Michelakakis H, Hadziyannis S. Systemic AL amyloidosis in Gaucher disease. A case report and review of the literature. Journal of Internal Medicine. 1999;246(6):587-90.
46. Deibener J, Kaminsky P, Jacob C, Dousset B, Klein M, Duc M. Enzyme replacement therapy decreases hypergammaglobulinemia in Gaucher's disease. Haematologica. 1998;83(5):479-80.
47. Anderson KC. The role of immunomodulatory drugs in multiple myeloma. Seminars in Hematology. 2003;40(4 Suppl 4):23-32.
48. Hattori Y, Kakimoto T, Okamoto S, Sato N, Ikeda Y. Thalidomide-induced severe neutropenia during treatment of multiple myeloma. International Journal of Hematology. 2004;79(3):283-8.
49. Ron I, Horowitz M. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Human Molecular Genetics. 2005;14(16):2387-98.
50. Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, Li H, Wang M, Yang J, Yi Q. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood. 2009;114(17):3625-8.
51. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29(8):1093-102.
52. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology. 2002;23(11):549-55.
53. Wang YC, He F, Feng F, Liu XW, Dong GY, Qin HY, Hu XB, Zheng MH, Liang L, Feng L, Liang YM, Han H. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Research. 2010;70(12):4840-9.
54. Nagai T, Tanaka M, Tsuneyoshi Y, Xu B, Michie SA, Hasui K, Hirano H, Arita K, Matsuyama T. Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta. Cancer Immunology, Immunotherapy:CII. 2009;58(10):1577-86.
55. Shi L, Lei D, Ma C, Xu F, Li Y, Wang Y, Cong N, Liu D, Pan XL. Clinicopathological implications of tumour-associated macrophages and vascularization in sinonasal melanoma. The Journal of International Medical Research. 2010;38(4):1276-86.
56. Nonomura N, Takayama H, Nakayama M, Nakai Y, Kawashima A, Mukai M, Nagahara A, Aozasa K, Tsujimura A. Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU International. 2011;107(12):1918-22.
57. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Current Opinion in Immunology. 2010;22(2):231-7.
58. Roodman GD. Pathogenesis of myeloma bone disease. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2009;23(3):435-41.
59. Boot RG, Verhoek M, de Fost M, Hollak CE, Maas M, Bleijlevens B, van Breemen MJ, van Meurs M, Boven LA, Laman JD, Moran MT, Cox TM, Aerts JM. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood. 2004;103(1):33-9.
60. Regazzoli A, Pozzi A, Rossi G. Pseudo-Gaucher plasma cells in the bone marrow of a patient with monoclonal gammopathy of undetermined significance. Haematologica. 1997;82(6):727.
61. Shenjere P, Roy A, Eyden B, Banerjee SS. Pseudo-Gaucher cells in multiple myeloma. International Journal of Surgical Pathology. 2008;16(2):176-9.
62. Florena AM, Franco V, Campesi G. Immunophenotypical comparison of Gaucher's and pseudo-Gaucher cells. Pathology International. 1996;46(2):155-60.
63. Kampine JP, Brady RO, Kanfer JN, Feld M, Shapiro D. Diagnosis of gaucher's disease and niemann-pick disease with small samples of venous blood. Science. 1967;155(758):86-8.
64. Zidar BL, Hartsock RJ, Lee RE, Glew RH, LaMarco KL, Pugh RP, Raju RN, Shackney SE. Pseudo-Gaucher cells in the bone marrow of a patient with Hodgkin's disease. American Journal of Clinical Pathology. 1987;87(4):533-6.
65. Papadimitriou JC, Chakravarthy A, Heyman MR. Pseudo-Gaucher cells preceding the appearance of immunoblastic lymphoma. American Journal of Clinical Pathology. 1988;90(4):454-8.
66. Anastasi J, Musvee T, Roulston D, Domer PH, Larson RA, Vardiman JW. Pseudo-Gaucher histiocytes identified up to 1 year after transplantation for CML are BCR/ABL-positive. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 1998;12(2):233-7.
67. Stewart AJ, Jones RD. Pseudo-Gaucher cells in myelodysplasia. Journal of Clinical Pathology. 1999;52(12):917-8.
68. Knox-Macaulay H, Bhusnurmath S, Alwaily A. Pseudo-Gaucher's cells in association with common acute lymphoblastic leukemia. Southern Medical Journal. 1997;90(1):69-71.
69. Boven LA, van Meurs M, Boot RG, Mehta A, Boon L, Aerts JM, Laman JD. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. American Journal of Clinical Pathology. 2004;122(3):359-69.
70. Sharma P, Khurana N, Singh T. Pseudo-Gaucher cells in Hb E disease and thalassemia intermedia. Hematology. 2007;12(5):457-9. Epub 2007/09/14.
71. Bain BJ, Lee L. Pseudo-Gaucher cells in sickle cell anemia. American Journal of Hematology. 2010;85(6):435.
72. Kaloterakis A, Filiotou A, Konstantopoulos K, Rombos Y, Bossinakou I, Hadziyannis S. Multiple myeloma in sickle cell syndromes. Haematologia. 2001;31(2):153-9.
73. Sandstrom H, Wahlin A, Eriksson M, Bergstrom I, Wickramasinghe SN. Intravascular haemolysis and increased prevalence of myeloma and monoclonal gammopathy in congenital dyserythropoietic anaemia, type III. European Journal of Haematology. 1994;52(1):42-6.
74. Boot RG, Renkema GH, Verhoek M, Strijland A, Bliek J, de Meulemeester TM, Mannens MM, Aerts JM. The human chitotriosidase gene. Nature of inherited enzyme deficiency. The Journal of Biological Chemistry. 1998;273(40):25680-5.
75. Bargagli E, Maggiorelli C, Rottoli P. Human chitotriosidase: a potential new marker of sarcoidosis severity. Respiration; International Review of Thoracic Diseases. 2008;76(2):234-8.
76. Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. The Journal of Clinical Investigation. 1994;93(3):1288-92.
77. Baud'huin M, Duplomb L, Ruiz Velasco C, Fortun Y, Heymann D, Padrines M. Key roles of the OPG-RANK-RANKL system in bone oncology. Expert Review of Anticancer Therapy. 2007;7(2):221-32.
78. Yavropoulou MP, Yovos JG. Osteoclastogenesis--current knowledge and future perspectives. Journal of Musculoskeletal & Neuronal Interactions. 2008;8(3):204-16.
79. Boyce BF, Xing L. The RANKL/RANK/OPG pathway. Current Osteoporosis Reports. 2007;5(3):98-104.
80. Roato I, Grano M, Brunetti G, Colucci S, Mussa A, Bertetto O, Ferracini R. Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. The FASEB journal: Official Publication of the Federation of American Societies for Experimental Biology. 2005;19(2):228-30.
81. Adamopoulos IE, Wordsworth PB, Edwards JR, Ferguson DJ, Athanasou NA. Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis. Human Pathology. 2006;37(9):1176-85.
82. Breuil V, Cosman F, Stein L, Horbert W, Nieves J, Shen V, Lindsay R, Dempster DW. Human osteoclast formation and activity in vitro: effects of alendronate. Journal of bone and mineral research: The Official Journal of the American Society for Bone and Mineral Research. 1998;13(11):1721-9.
83. Josselin N, Libouban H, Dib M, Ifrah N, Legrand E, Basle MF, Audran M, Chappard D. Quantification of dendritic cells and osteoclasts in the bone marrow of patients with monoclonal gammopathy. Pathology Oncology Research: POR. 2009;15(1):65-72.
84. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, Kido S, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood. 2004;104(8):2484-91.
85. Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B, Epstein J. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Research. 2004;64(6):2016-23.
86. Hecht M, von Metzler I, Sack K, Kaiser M, Sezer O. Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA). Experimental Cell Research. 2008;314(5):1082-93.
87. Monti M, Scazzoso A, Calzaferri G, Santi I, D'Aprile E, Cunietti E. Tartrate-resistant acid phosphatase (TRAP) activity in serum: potential use in assessing bone resorption in patients with multiple myeloma. The International Journal of Biological Markers. 1990;5(2):61-4.
88. Abe M, Hiura K, Ozaki S, Kido S, Matsumoto T. Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production. Journal of Bone and Mineral Metabolism. 2009;27(1):16-23.
89. Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD, Alsina M. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood. 2000;96(2):671-5.
90. Hashimoto T, Abe M, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. British Journal of Haematology. 2004;125(1):38-41.
91. Hongming H, Jian H. Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6. Leukemia Research. 2009;33(1):115-22.
92. Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C, Chauhan D, Okawa Y, Munshi NC, Richardson PG, Anderson KC. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2008;22(10):1925-32.
93. Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V, Donnenberg A, Ghobrial I, Mapara MY, Stirling D, Roodman D, Lentzsch S. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood. 2006;107(8):3098-105.
94. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010 Dec 11;376(9757):1989-99.
95. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ, Zimran A. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Archives of Internal Medicine. 2000;160(18):2835-43.
96. Chamberlain P, Compston J, Cox TM, Hayman AR, Imrie RC, Reynolds K, Holmes SD. Generation and characterization of monoclonal antibodies to human type-5 tartrate-resistant acid phosphatase: development of a specific immunoassay of the isoenzyme in serum. Clinical Chemistry. 1995;41(10):1495-
97. Drugan C, Jebeleanu G, Grigorescu-Sido P, Caillaud C, Craciun AM. Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease. Blood Cells, Molecules & Diseases. 2002;28(1):13-20.
98. Fiore CE, Barone R, Pennisi P, Pavone V, Riccobene S. Bone ultrasonometry, bone density, and turnover markers in type 1 Gaucher disease. Journal of Bone and Mineral Metabolism. 2002;20(1):34-8.
99. Hollak CE, Evers L, Aerts JM, van Oers MH. Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells, Molecules & Diseases. 1997;23(2):201-12.
100. van Breemen MJ, de Fost M, Voerman JS, Laman JD, Boot RG, Maas M, Hollak CE, Aerts JM, Rezaee F. Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochimica et Biophysica Acta. 2007;1772(7):788-96.
101. Magal I, Lebel E, Altarescu G, Itzchaki M, Rudensky B, Foldes AJ, Zimran A, Elstein D. Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease. British Journal of Haematology. 2006;133(1):93-7.
102. Yaccoby S. Osteoblastogenesis and tumor growth in myeloma. Leukemia & Lymphoma. 2010;51(2):213-20.
103. Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D, Ling W, Saha R, Barlogie B, Tricot G, Epstein J. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica. 2006;91(2):192-9.
104. Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J, Barlogie B, Shaughnessy JD, Jr. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood. 2008;112(1):196-207.
105. Sezer O. Myeloma bone disease: recent advances in biology, diagnosis, and treatment. The Oncologist. 2009;14(3):276-83.
106. Li X, Pennisi A, Yaccoby S. Role of decorin in the antimyeloma effects of osteoblasts. Blood. 2008;112(1):159-68.
107. Kaiser M, Mieth M, Liebisch P, Oberlander R, Rademacher J, Jakob C, Kleeberg L, Fleissner C, Braendle E, Peters M, Stover D, Sezer O, Heider U. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. European Journal of Haematology. 2008;80(6):490-4.
108. Pastores GM, Wallenstein S, Desnick RJ, Luckey MM. Bone density in Type 1 Gaucher disease. Journal of bone and mineral research: The Official Journal of the American Society for Bone and Mineral Research. 1996;11(11):1801-7.
109. Ciana G, Martini C, Leopaldi A, Tamaro G, Katouzian F, Ronfani L, Bembi B. Bone marker alterations in patients with type 1 Gaucher disease. Calcified Tissue International. 2003;72(3):185-9.
110. Mikosch P, Reed M, Baker R, Holloway B, Berger L, Mehta AB, Hughes DA. Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat. Calcified Tissue International. 2008;83(1):43-54.
111. Mistry PK, Liu J, Yang M, Nottoli T, McGrath J, Jain D, Zhang K, Keutzer J, Chuang WL, Mehal WZ, Zhao H, Lin A, Mane S, Liu X, Peng YZ, Li JH, Agrawal M, Zhu LL, Blair HC, Robinson LJ, Iqbal J, Sun L, Zaidi M. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(45):19473-8.
112. Morjani H, Aouali N, Belhoussine R, Veldman RJ, Levade T, Manfait M. Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets. International Journal of Cancer Journal International du Cancer. 2001;94(2):157-65.
113. Struckhoff AP, Bittman R, Burow ME, Clejan S, Elliott S, Hammond T, Tang Y, Beckman BS. Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. The Journal of Pharmacology and Experimental Therapeutics. 2004;309(2):523-32.
114. Gerrard G, Butters TD, Ganeshaguru K, Mehta AB. Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity. European Journal of Pharmacology. 2009;609(1-3):34-9.
115. Brown LM, Gridley G, Check D, Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood. 2008;111(7):3388-94.
116. Dispenzieri A, Gertz MA, Therneau TM, Kyle RA. Retrospective cohort study of 148 patients with polyclonal gammopathy. Mayo Clinic Proceedings Mayo Clinic. 2001;76(5):476-87.
117. Kelly C, Baird G, Foster H, Hosker H, Griffiths I. Prognostic significance of paraproteinaemia in rheumatoid arthritis. Annals of the Rheumatic Diseases. 1991;50(5):290-4.
118. Shoenfeld Y, Gallant LA, Shaklai M, Livni E, Djaldetti M, Pinkhas J. Gaucher's disease: a disease with chronic stimulation of the immune system. Archives of Pathology & Laboratory Medicine. 1982;106(8):388-91.
119. Cox TM. Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses. Journal of Inherited Metabolic Disease. 2001;24 Suppl 2:106-21; discussion 87-8.
120. Allen MJ, Myer BJ, Khokher AM, Rushton N, Cox TM. Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. QJM: Monthly Journal of the Association of Physicians. 1997;90(1):19-25.
121. Michelakakis H, Spanou C, Kondyli A, Dimitriou E, Van Weely S, Hollak CE, Van Oers MH, Aerts JM. Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease. Biochimica et Biophysica Acta. 1996;1317(3):219-22.
122. Barak V, Acker M, Nisman B, Kalickman I, Abrahamov A, Zimran A, Yatziv S. Cytokines in Gaucher's disease. European Cytokine Network. 1999;10(2):205-10.
123. Mizukami H, Mi Y, Wada R, Kono M, Yamashita T, Liu Y, Werth N, Sandhoff R, Sandhoff K, Proia RL. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. The Journal of Clinical Investigation. 2002;109(9):1215-21.
124. Katusic S, Beard CM, Kurland LT, Weis JW, Bergstralh E. Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. The American Journal of Medicine. 1985;78(1A):50-5.
125. Carew JS, Nawrocki ST, Cleveland JL. Modulating autophagy for therapeutic benefit. Autophagy. 2007;3(5):464-7.
126. Sun Y, Grabowski GA. Impaired autophagosomes and lysosomes in neuronopathic Gaucher disease. Autophagy. 2010;6(5).
127. Montelli TC, Peracoli MT, Gabarra RC, Soares AM, Kurokawa CS. Familial cancer: depressed NK-cell cytotoxicity in healthy and cancer affected members. Arquivos de Neuro-Psiquiatria. 2001;59(1):6-10.
128. Peracoli MT, Montelli TC, Soares AM, Parise-Fortes MR, Alquati SA, Ueda A, Montenegro MR, Alves A, Gabarra RC, Faleiros TP, Zanini MA. Immunological alterations in patients with primary tumors in central nervous system. Arquivos de Neuro-Psiquiatria. 1999;57(3A):539-46.
129. Ege H, Gertz MA, Markovic SN, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Porrata LF. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. British Journal of Haematology. 2008;141(6):792-8.
130. Mocikova H. Prognostic significance of absolute lymphocyte count and lymphocyte subsets in lymphomas. Prague Medical Report. 2010;111(1):5-11.
131. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. British Journal of Haematology. 2007;138(5):563-79.
132. Qiu H, Xiao-Jun W, Zhi-Wei Z, Gong C, Guo-Qiang W, Li-Yi Z, Yuan-Fang L, Rajiv-Prasad K. The prognostic significance of peripheral T-lymphocyte subsets and natural killer cells in patients with colorectal cancer. Hepato-gastroenterology. 2009;56(94-95):1310-5.
133. Yoneda K, Morii T, Nieda M, Tsukaguchi N, Amano I, Tanaka H, Yagi H, Narita N, Kimura H. The peripheral blood Valpha24+ NKT cell numbers decrease in patients with haematopoietic malignancy. Leukemia Research. 2005;29(2):147-52.
134. Dewan MZ, Takada M, Terunuma H, Deng X, Ahmed S, Yamamoto N, Toi M. Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2009;63(9):703-6.
135. Ogmundsdottir HM. Natural killer cell activity in patients with multiple myeloma. Cancer Detection and Prevention. 1988;12(1-6):133-43.
136. Deane S, Selmi C, Naguwa SM, Teuber SS, Gershwin ME. Common variable immunodeficiency: etiological and treatment issues. International Archives of Allergy and Immunology. 2009;150(4):311-24.
137. Osterborg A, Nilsson B, Bjorkholm M, Holm G, Mellstedt H. Natural killer cell activity in monoclonal gammopathies: relation to disease activity. European Journal of Haematology. 1990;45(3):153-7.
138. Plonquet A, Haioun C, Jais JP, Debard AL, Salles G, Bene MC, Feugier P, Rabian C, Casasnovas O, Labalette M, Kuhlein E, Farcet JP, Emile JF, Gisselbrecht C, Delfau-Larue MH. Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. Annals of oncology: Official Journal of the European Society for Medical Oncology / ESMO. 2007;18(7):1209-15.
139. Palmer S, Hanson CA, Zent CS, Porrata LF, Laplant B, Geyer SM, Markovic SN, Call TG, Bowen DA, Jelinek DF, Kay NE, Shanafelt TD. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. British Journal of Haematology. 2008;141(5):607-14.
140. Marti GE, Ryan ET, Papadopoulos NM, Filling-Katz M, Barton N, Fleischer TA, Rick M, Gralnick HR. Polyclonal B-cell lymphocytosis and hypergammaglobulinemia in patients with Gaucher disease. American Journal of Hematology. 1988;29(4):189-94.
141. Balreira A, Lacerda L, Miranda CS, Arosa FA. Evidence for a link between sphingolipid metabolism and expression of CD1d and MHC-class II: monocytes from Gaucher disease patients as a model. British Journal of Haematology. 2005;129(5):667-76.
142. Balreira A, Cavallari M, Sa Miranda MC, Arosa FA. Uncoupling between CD1d upregulation induced by retinoic acid and conduritol-B-epoxide and iNKT cell responsiveness. Immunobiology. 2010;215(6):505-13.
143. Lacerda L, Arosa FA, Lacerda R, Cabeda J, Porto G, Amaral O, Fortuna A, Pinto R, Oliveira P, McLaren CE, Sa Miranda C, de Sousa M. T cell numbers relate to bone involvement in Gaucher disease. Blood Cells, Molecules & Diseases. 1999;25(2):130-8.
144. Burstein Y, Zakuth V, Rechavi G, Spirer Z. Abnormalities of cellular immunity and natural killer cells in Gaucher's disease. Journal of Clinical & Laboratory Immunology. 1987;23(3):149-51.
145. Bruck W, Goebel HH, Dienes P. B and T lymphocytes are affected in lysosomal disorders--an immunoelectron microscopic study. Neuropathology and Applied Neurobiology. 1991;17(3):219-22.
146. Maret A, Salvayre R, Livni N, Icart J, Vuillaume M, Douste-Blazy L. Biochemical and ultrastructural findings in Epstein-Barr virus-transformed lymphoid cell lines from type 1 Gaucher disease. Biology of the cell / under the auspices of the European Cell Biology Organization. 1987;59(1):101-4.
147. Laszlo A, Karcsu S, Havass Z. Ultrastructural study of peripheral lymphocytes and polymorphonuclear leukocytes in children with lysosomal enzymopathies and hyperlipoproteinemia. Acta Paediatrica Hungarica. 1987;28(3-4):163-73.
148. Khalifa A TA, Sherif E, Sadek A, Tiseer N. Immune dysfunction in patients with Gaucher disease:Impact of disease severity and enzyme replacement therapy [abstract]. Haematologica. 2010;95:1.
149. Bassan R, Montanelli A, Barbui T. Interaction between a serum factor and T lymphocytes in Gaucher disease. American Journal of Hematology. 1985;18(4):381-4.
150. Metelitsa LS. Flow cytometry for natural killer T cells: multi-parameter methods for multifunctional cells. Clin Immunol. 2004;110(3):267-76.
151. Terabe M, Berzofsky JA. The role of NKT cells in tumor immunity. Advances in Cancer Research. 2008;101:277-348.
152. Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, Balk SP, Exley MA. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol. 2001;167(7):4046-50.
153. Kawano T, Nakayama T, Kamada N, Kaneko Y, Harada M, Ogura N, Akutsu Y, Motohashi S, Iizasa T, Endo H, Fujisawa T, Shinkai H, Taniguchi M. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Research. 1999;59(20):5102-5.
154. Taniguchi M, Tashiro T, Dashtsoodol N, Hongo N, Watarai H. The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy. International Immunology. 2010;22(1):1-6.
155. Speak AO, Cerundolo V, Platt FM. CD1d presentation of glycolipids. Immunology and Cell Biology. 2008;86(7):588-97.
156. Lalazar G, Preston S, Zigmond E, Ben Yaacov A, Ilan Y. Glycolipids as immune modulatory tools. Mini Reviews in Medicinal Chemistry. 2006;6(11):1249-53.
157. Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, Jagannath S, Dhodapkar MV. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006;108(2):618-21.
158. Castaneda JA, Lim MJ, Cooper JD, Pearce DA. Immune system irregularities in lysosomal storage disorders. Acta Neuropathologica. 2008;115(2):159-74.
159. Gadola SD, Silk JD, Jeans A, Illarionov PA, Salio M, Besra GS, Dwek R, Butters TD, Platt FM, Cerundolo V. Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases. The Journal of Experimental Medicine. 2006;203(10):2293-303.
160. Liel Y, Rudich A, Nagauker-Shriker O, Yermiyahu T, Levy R. Monocyte dysfunction in patients with Gaucher disease: evidence for interference of glucocerebroside with superoxide generation. Blood. 1994;83(9):2646-53.
161. Micheva I, Marinakis T, Repa C, Kouraklis-Symeonidis A, Vlacha V, Anagnostopoulos N, Zoumbos N, Symeonidis A. Dendritic cells in patients with type I Gaucher disease are decreased in number but functionally normal. Blood Cells, Molecules & Diseases. 2006;36(2):298-307.
162. Metcalfe KA, Poll A, Royer R, Llacuachaqui M, Tulman A, Sun P, Narod SA. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010;28(3):387-91.
163. Stone DL, Tayebi N, Orvisky E, Stubblefield B, Madike V, Sidransky E. Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease. Human Mutation. 2000;15(2):181-8.
164. Chen L, Chan TH, Guan XY. Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma. Acta Pharmacologica Sinica. 2010;31(9):1165-71.
165. Fabris S, Ronchetti D, Agnelli L, Baldini L, Morabito F, Bicciato S, Basso D, Todoerti K, Lombardi L, Lambertenghi-Deliliers G, Neri A. Transcriptional features of multiple myeloma patients with chromosome 1q gain. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2007;21(5):1113-6.
166. Pinkhas J, Djaldetti M, Yaron M. Coincidence of multiple myeloma with Gaucher's disease. Israel Journal of Medical Sciences. 1965;1(4):537-40.
167. Gal R, Gukovsky-Oren S, Floru S, Djaldetti M, Kessler E. Sequential appearance of breast carcinoma, multiple myeloma and Gaucher's disease. Haematologica. 1988;73(1):63-5.
168. Garfinkel D, Sidi Y, Ben-Bassat M, Salomon F, Hazaz B, Pinkhas J. Coexistence of Gaucher's disease and multiple myeloma. Archives of Internal Medicine. 1982;142(12):2229-30.
169. Garfinkel D, Salamon F, Sidi Y, Ben-Bassat M, Lubin E, Pinkhas J. Multiple plasmocytomas of the liver and the spleen. Clinical Nuclear Medicine. 1985;10(11):819.
170. Bruckstein AH, Karanas A, Dire JJ. Gaucher's disease associated with Hodgkin's disease. The American Journal of Medicine. 1980;68(4):610-3.
171. Sharer LR, Barondess JA, Silver RT, Gray GF. Association of Hodgkin disease and Gaucher disease. Archives of Pathology. 1974;98(6):376-8.
172. Goodman S. Nodular sclerosing Hodgkin's disease in association with Gaucher's disease. Clinical Radiology. 1988;39(3):326-7.
173. Fox H, McCarthy P, Andre-Schwartz J, Shoenfeld Y, Miller KB. Gaucher's disease and chronic lymphocytic leukemia. Possible pathogenetic link between Gaucher's disease and B-cell proliferations? Cancer. 1984;54(2):312-4.
174. Kaufman S, Rozenfeld V, Yona R, Varon M. Gaucher's disease associated with chronic lymphocytic leukaemia. Clinical and Laboratory Haematology. 1986;8(4):321-4.
175. Marsh RD, Killeen RB, Jr., Agaliotis D. Gaucher's disease associated with chronic lymphocytic leukemia. Southern Medical Journal. 1993;86(4):473-5.
176. Chang-Lo M, Yam LT, Rubenstone AI, Schwartz SO. Gaucher's disease associated with chronic lymphocytic leukaemia, gout and carcinoma. The Journal of Pathology. 1975;116(4):203-7.
177. Paulson JA, Marti GE, Fink JK, Sato N, Schoen M, Karcher DS. Richter's transformation of lymphoma complicating Gaucher's disease. Hematologic Pathology. 1989;3(2):91-6.
178. Carreiro J, Balwani M, Grosskreutz C, Isola L, Malone A, Scigliano E, Osman K. A case report of secondary autograft failure due to Gaucher disease. American Journal of Hematology. 2008;83(12):937.
179. Perales M, Cervantes F, Cobo F, Montserrat E. Non-Hodgkin's lymphoma associated with Gaucher's disease. Leukemia & Lymphoma. 1998;31(5-6):609-12.
180. Shvidel L, Sigler E, Shtalrid M, Feldberg E, Berrebi A. Parotid gland involvement, the presenting sign of high grade non-Hodgkin lymphoma in two patients with Gaucher disease and sicca syndrome. Journal of Inherited Metabolic Disease. 2007;30(5):825.
181. Manz M, Riessen R, Poll L, Dohmen B, Kaiserling E, Kruck W, Laniado M, Kanz L, Denzlinger C. High-grade lymphoma mimicking bone crisis in Gaucher's disease. British Journal of Haematology. 2001;113(1):191-3.
182. Sanchez R, Etzell J, Kim G, Packman S, Fairley C, Goldsby R. Pediatric malignancies. Case 2. Peripheral T-cell lymphoma in an adolescent with unsuspected Gaucher disease. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2005;23(21):4792-3.
183. Hrebicek M, Zeman J, Musilova J, Hodanova K, Renkema GH, Veprekova L, Ledvinova J, Hrebicek D, Sokolova J, Aerts JM, Elleder M. A case of type I Gaucher disease with cardiopulmonary amyloidosis and chitotriosidase deficiency. Virchows Archiv: An International Journal of Pathology. 1996;429(4-5):305-9.
184. Krishnan B, Ganeshaguru K, Baker R, Richfield L, Mehta AB. Multidrug resistance and myelomonocytic leukaemia in gaucher's disease. Haematologica. 2003;88(2):ECR02.
185. Castelli R, Cassinerio E, Iurlo A, Zanella A, Gianelli U, Cappellini MD. Unusual severe development of common B lymphoblastic leukemia in Gaucher disease type I. American Journal of Hematology. 2006;81(5):383-4.
186. Krause JR, Bures C, Lee RE. Acute leukaemia and Gaucher's disease. Scandinavian Journal of Haematology. 1979;23(2):115-8.
187. Burstein Y, Rechavi G, Rausen AR, Frisch B, Spirer Z. Association of Gaucher's disease and lymphoid malignancy in 2 children. Scandinavian Journal of Haematology. 1985;35(4):445-7.
188. Corbett GM, Darbyshire PJ, Besley GT, Parker AC. Adult Gaucher disease in association with acute leukaemia. Postgraduate Medical Journal. 1987;63(744):899-900.
189. Shinar E, Gershon ZL, Leiserowitz R, Matzner Y, Yatziv S, Polliack A. Coexistence of Gaucher Disease and Philadelphia positive chronic granulocytic leukemia. American Journal of Hematology. 1982;12(2):199-202.
190. Petrides PE, leCoutre P, Muller-Hocker J, Magin E, Harzer K, Demina A, Beutler E. Coincidence of Gaucher's disease due to a private mutation and Ph' positive chronic myeloid leukemia. American Journal of Hematology. 1998;59(1):87-90.
191. Breiden-Langen CM, Buchsel R, Brambs HJ, Oehlert M, Matern S. [Coincidence of Gaucher disease with primary hepatocellular carcinoma]. Leber, Magen, Darm. 1991;21(3):126, 9-30. Koinzidenz eines Morbus Gaucher mit primarem hepatozellularem Karzinom.
192. Erjavec Z, Hollak CE, de Vries EG. Hepatocellular carcinoma in a patient with Gaucher disease on enzyme supplementation therapy. Annals of oncology: Official Journal of the European Society for Medical Oncology / ESMO. 1999;10(2):243.
193. Xu R, Mistry P, McKenna G, Emre S, Schiano T, Bu-Ghanim M, Levi G, Fiel MI. Hepatocellular carcinoma in type 1 Gaucher disease: a case report with review of the literature. Seminars in Liver Disease. 2005;25(2):226-9.
194. Kenan S, Abdelwahab IF, Hermann G, Klein M, Pastores G. Osteoblastoma of the humerus associated with type-I Gaucher's disease. A case report. The Journal of Bone and Joint Surgery British Volume. 1996;78(5):702-5.
195. Bohm P, Kunz W, Horny HP, Einsele H. Adult Gaucher disease in association with primary malignant bone tumors. Cancer. 2001;91(3):457-62.
196. Tsung SH, Cotes E. Coexistence of bronchogenic carcinoma and Gaucher disease. Archives of Pathology & Laboratory Medicine. 1977;101(1):56.
197. Leone JP, Dudek AZ. Enzyme replacement therapy for Gaucher's disease in patient treated for non-small cell lung cancer. Anticancer Research. 2008;28(6B):3937-9.
198. Pins MR, Mankin HJ, Xavier RJ, Rosenthal DI, Dickersin GR, Rosenberg AE. Malignant epithelioid hemangioendothelioma of the tibia associated with a bone infarct in a patient who had Gaucher disease. A case report. The Journal of Bone and Joint Surgery American volume. 1995;77(5):777-81.
199. Lyons JC, Scheithauer BW, Ginsburg WW. Gaucher's disease and glioblastoma multiforme in two siblings: a clinicopathologic study. Journal of Neuropathology and Experimental Neurology. 1982;41(1):45-53.
200. Kojiro M, Kage M, Abe H, Imamura M, Shiraishi K, Mizoguchi M. Association of dysgerminoma and gaucher's disease. Cancer. 1983;51(4):712-5.